Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings

Creative Commons License

Akinci B., Subauste A., Ajluni N., Esfandiari N. H., Meral R., Neidert A. H., ...More

MED, vol.2, no.7, pp.814-842, 2021 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 2 Issue: 7
  • Publication Date: 2021
  • Doi Number: 10.1016/j.medj.2021.04.001
  • Journal Name: MED
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.814-842
  • Open Archive Collection: AVESIS Open Access Collection
  • Dokuz Eylül University Affiliated: No

Abstract

Background: Recombinant leptin therapy reverses nonalcoholic steatohepatitis (NASH) in leptin-deficient lipodystrophy. We inquired if leptin therapy would improve NASH in more common forms of this heterogeneous condition.